Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 844

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies

Open access
Adams, Denise M., Trenor, Cameron C., Hammill, Adrienne M., Vinks, Alexander A., Patel, Manish N., Chaudry, Gulraiz, Wentzel, Mary Sue, Mobberley-Schuman, Paula S., Campbell, Lisa M., Brookbank, Christine, Gupta, Anita, Chute, Carol, Eile, Jennifer, McKenna, Jesse, Merrow, Arnold C., Fei, Lin, Hornung, Lindsey, Seid, Michael, Dasgupta, A. Roshni, Dickie, Belinda H., Elluru, Ravindhra G., Lucky, Anne W., Weiss, Brian, Azizkhan, Richard G.·2016·Pediatrics

Abstract

BACKGROUND AND OBJECTIVES: Complicated vascular anomalies have limited therapeutic options and cause significant morbidity and mortality. This Phase II trial enrolled patients with complicated vascular anomalies to determine the efficacy and safety of treatment with sirolimus for 12 courses; each course was defined as 28 days. METHODS: Treatment consisted of a continuous dosing schedule of oral sirolimus starting at 0.8 mg/m2 per dose twice daily, with pharmacokinetic-guided target serum trough levels of 10 to 15 ng/mL. The primary outcomes were responsiveness to sirolimus by the end of course 6 (evaluated according to functional impairment score, quality of life, and radiologic assessment) and the incidence of toxicities and/or infection-related deaths. RESULTS: Sixty-one patients were enrolled; 57 patients were evaluable for efficacy at the end of course 6, and 53 were evaluable at the end of course 12. No patient had a complete response at the end of course 6 or 12 as anticipated. At the end of course 6, a total of 47 patients had a partial response, 3 patients had stable disease, and 7 patients had progressive disease. Two patients were taken off of study medicine secondary to persistent adverse effects. Grade 3 and higher toxicities attributable to sirolimus included blood/bone marrow toxicity in 27% of patients, gastrointestinal toxicity in 3%, and metabolic/laboratory toxicity in 3%. No toxicity-related deaths occurred. CONCLUSIONS: Sirolimus was efficacious and well tolerated in these study patients with complicated vascular anomalies. Clinical activity was reported in the majority of the disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1542/peds.2015-3257

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 844

Metadata

Authors
Adams, D. M., Trenor, C. C., Hammill, A. M., Vinks, A. A., Patel, M. N., Chaudry, G., Wentzel, M. S., Mobberley-Schuman, P. S., Campbell, L. M., Brookbank, C., Gupta, A., Chute, C., Eile, J., McKenna, J., Merrow, A. C., Fei, L., Hornung, L., Seid, M., Dasgupta, A. R., Dickie, B. H., Elluru, R. G., Lucky, A. W., Weiss, B., & Azizkhan, R. G.
Venue
Pediatrics
Published
2016-02-01
Volume
137
Issue
2
Pages
e20153257-e20153257
ISSN
  • 0031-4005 (ISSN-L)
  • 1098-4275
OpenAlex
W2392938395
Cited by
844
References
18
FWCI
74.68
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. https://app.cochat.ai/papers/10.1542/peds.2015-3257
The paper
Adams, D. M., Trenor, C. C., Hammill, A. M., Vinks, A. A., Patel, M. N., Chaudry, G., Wentzel, M. S., Mobberley-Schuman, P. S., Campbell, L. M., Brookbank, C., Gupta, A., Chute, C., Eile, J., McKenna, J., Merrow, A. C., Fei, L., Hornung, L., Seid, M., Dasgupta, A. R., . . . Azizkhan, R. G. (2016). Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics. https://doi.org/10.1542/peds.2015-3257

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.